WASHINGTON–(BUSINESS WIRE)–#AR—Altoida, a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today it will be presenting poster presentations at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Boston and online, October 24-27, 2023.
“We look forward to presenting new data at CTAD 2023, that highlight Altoida’s latest research. Our presented data exemplifies our commitment to advancing the field of Alzheimer’s disease through cutting-edge technology and data-driven insights,” said Marc Jones, CEO of Altoida. “Digital biomarkers have the potential to revolutionize our understanding of Alzheimer’s and transform research, clinical trials, and patient diagnosis and treatment. We eagerly anticipate collaborative efforts with our partners in early disease detection and treatment.”
Details of the poster presentations are below:
Poster Title: Correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers
Poster Number: P189
Date/Time: Friday, October 27, 8 am to 5 pm
Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida
Poster Title: Building an Evidence Library of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer’s Disease and Related Dementias Clinical Trials
Poster Number: P190
Date/Time: Friday, October 27, 8 am to 5 pm
Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida
About Altoida
Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com. Follow us on Twitter @altoida.
Contacts
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
SALEM, MA / ACCESS Newswire / April 19, 2026 / Dekáf Coffee Roasters has introduced…
SUNNY ISLES BEACH, FL / ACCESS Newswire / April 18, 2026 / Elektros Inc. today…
Former residential patient's civil suit against operator of The Pointe Malibu Recovery Center reaches contested…
General Compute today announced its inference cloud platform built for AI agents, working with early…
Free, family-friendly hometown debut invites aspiring young chefs and food lovers to meet and celebrate…
The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo…
